Skip to main content
OpenTrials
Completed

NCT Number: NCT03372200

Febuxostat-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout

FYU-981 or Febuxostat are administrated to hyperuricemia patients (underexcretion and mixed types) with or without gout for 14 weeks to compare the efficacy and safety of these drugs by the method of multicenter, randomized, double-blind, ascending dose regimen.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hyperuricemia With or Without Gout

Age range

20 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Mochida Investigational sites

Tokyo, Japan

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Serum urate level:
  • >= 7.0mg/dL in patients with gouty nodule or with history of gout, or >= 8.0mg/dL in patients with hypertension, diabetes or metabolic syndrome, or >= 9.0mg/dL
  • Disease type in the classification of hyperuricemia: Uric acid-underexcretion type or mixed type
  • Outpatients

Exclusion criteria

  • Gouty arthritis within 14 days before randomized allocation
  • Secondary hyperuricemia
  • HbA1c: >= 8.4%
  • Clinically significant cardiac, hepatic, renal, hematologic or endocrine disease
  • Kidney calculi or clinically significant urinary calculi
  • AST: >= 100 IU/L or ALT: >= 100 IU/L
  • eGFR: < 30 mL/min/1.73m^2
  • Systolic blood pressure: >= 180 mmHg or diastolic blood pressure: >= 110 mmHg

Treatment and study plan

FYU-981

Drug

Oral daily dosing for 14 weeks

Febuxostat

Drug

Oral daily dosing for 14 weeks

Primary outcomes

  1. Percent reduction from baseline in serum urate level at the final visit

    Time frame: 14 weeks

    Percent reduction from baseline in serum urate level at the final visit

Sponsors and collaborators

Lead sponsor

Mochida Pharmaceutical Company, Ltd.

Industry

Collaborators

  • Fuji Yakuhin Co., Ltd.

Registry information

Official study title

Febuxostat-Controlled, Double-Blind, Comparative Study of FYU-981 for Hyperuricemia With or Without Gout to Evaluate the Safety and Noninferiority of FYU-981 (Phase III Study)

Important dates

Study start
2018
Primary completion
2018
Study completion
2018
First posted
Dec 13, 2017
Registry last updated
Sep 24, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.